Name | Number of supported studies | Average coverage | |
---|---|---|---|
basal cell | 8 studies | 33% ± 18% | |
secretory cell | 6 studies | 46% ± 17% | |
squamous epithelial cell | 4 studies | 41% ± 20% | |
epithelial cell | 4 studies | 51% ± 7% | |
ciliated cell | 4 studies | 30% ± 15% | |
fibroblast | 4 studies | 28% ± 14% | |
luminal cell of prostate epithelium | 4 studies | 54% ± 15% | |
duct epithelial cell | 3 studies | 26% ± 5% | |
retinal pigment epithelial cell | 3 studies | 31% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
prostate | 3 studies | 33% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 6872.69 | 245 / 245 | 100% | 174.91 | 501 / 502 |
esophagus | 99% | 1378.14 | 1429 / 1445 | 80% | 10.79 | 147 / 183 |
uterus | 99% | 844.06 | 169 / 170 | 69% | 12.02 | 318 / 459 |
bladder | 95% | 1316.71 | 20 / 21 | 71% | 9.50 | 358 / 504 |
breast | 97% | 1922.04 | 446 / 459 | 66% | 6.61 | 735 / 1118 |
pancreas | 76% | 385.68 | 248 / 328 | 85% | 13.67 | 151 / 178 |
intestine | 98% | 1315.72 | 943 / 966 | 61% | 5.21 | 322 / 527 |
lung | 86% | 772.12 | 496 / 578 | 73% | 7.95 | 842 / 1155 |
stomach | 90% | 844.84 | 323 / 359 | 67% | 5.55 | 193 / 286 |
adrenal gland | 90% | 916.28 | 232 / 258 | 53% | 13.34 | 123 / 230 |
skin | 62% | 455.73 | 1114 / 1809 | 78% | 55.46 | 369 / 472 |
kidney | 61% | 385.81 | 54 / 89 | 52% | 4.71 | 467 / 901 |
ureter | 0% | 0 | 0 / 0 | 100% | 75.48 | 1 / 1 |
adipose | 100% | 3691.31 | 1198 / 1204 | 0% | 0 | 0 / 0 |
ovary | 53% | 433.25 | 95 / 180 | 31% | 1.95 | 135 / 430 |
thymus | 15% | 66.55 | 101 / 653 | 67% | 7.19 | 406 / 605 |
brain | 62% | 278.17 | 1631 / 2642 | 8% | 1.73 | 53 / 705 |
tonsil | 0% | 0 | 0 / 0 | 56% | 5.00 | 25 / 45 |
heart | 50% | 421.10 | 434 / 861 | 0% | 0 | 0 / 0 |
spleen | 41% | 169.13 | 100 / 241 | 0% | 0 | 0 / 0 |
muscle | 41% | 190.10 | 333 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 1.74 | 25 / 80 |
blood vessel | 30% | 232.07 | 397 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 24% | 1.16 | 7 / 29 |
liver | 12% | 39.42 | 26 / 226 | 10% | 0.76 | 42 / 406 |
peripheral blood | 2% | 18.63 | 15 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060166 | Biological process | olfactory pit development |
GO_0021768 | Biological process | nucleus accumbens development |
GO_0002072 | Biological process | optic cup morphogenesis involved in camera-type eye development |
GO_0050885 | Biological process | neuromuscular process controlling balance |
GO_0060013 | Biological process | righting reflex |
GO_0042573 | Biological process | retinoic acid metabolic process |
GO_0042574 | Biological process | retinal metabolic process |
GO_0060324 | Biological process | face development |
GO_0042572 | Biological process | retinol metabolic process |
GO_0031076 | Biological process | embryonic camera-type eye development |
GO_0070384 | Biological process | Harderian gland development |
GO_0002138 | Biological process | retinoic acid biosynthetic process |
GO_0042472 | Biological process | inner ear morphogenesis |
GO_0006915 | Biological process | apoptotic process |
GO_0048048 | Biological process | embryonic eye morphogenesis |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0007626 | Biological process | locomotory behavior |
GO_0051289 | Biological process | protein homotetramerization |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0004029 | Molecular function | aldehyde dehydrogenase (NAD+) activity |
GO_0001758 | Molecular function | retinal dehydrogenase activity |
GO_0004030 | Molecular function | aldehyde dehydrogenase [NAD(P)+] activity |
GO_0070403 | Molecular function | NAD+ binding |
GO_0070324 | Molecular function | thyroid hormone binding |
Gene name | ALDH1A3 |
Protein name | Aldehyde dehydrogenase 1 family member A3 Retinaldehyde dehydrogenase 3 (RALDH-3) (RalDH3) (EC 1.2.1.36) (Aldehyde dehydrogenase 6) (Aldehyde dehydrogenase family 1 member A3) (ALDH1A3) Aldehyde dehydrogenase 1 family member A3 (Aldehyde dehydrogenase 1 family, member A3, isoform CRA_b) |
Synonyms | hCG_28035 ALDH6 |
Description | FUNCTION: Catalyzes the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively (By similarity) . High specificity for all-trans-retinal as substrate, can also accept acetaldehyde as substrate in vitro but with lower affinity . Required for the biosynthesis of normal levels of retinoate in the embryonic ocular and nasal regions; a critical lipid in the embryonic development of the eye and the nasal region (By similarity). . |
Accessions | H0YKF9 ENST00000558033.5 ENST00000346623.6 H0YLT1 ENST00000329841.10 ENST00000557963.1 P47895 ENST00000561338.5 H0YNQ3 H0Y2X5 |